tbuckley/cabot-search huggingface dataset:
TCT-253 Impact of chronic kidney disease on in-hospital outcomes in patients with acute myocardial infarction: Insights from the J-MINUET study
Authors: Yukio Ozaki, Masaharu Ishihara, Masashi Fujino, Koichi Nakao, Satoshi Yasuda, Teruo Noguchi, Kazuo Kimura, Satoru Suwa, Kazuteru Fujimoto, Yasuharu Nakama, Takashi Morita, Wataru Shimizu, Yoshihiko Saito, Atsushi Hirohata, Yasuhiro Morita, Teruo Inoue, Atsunori Okamura, Masaaki Uematsu, Kazuhito Hirata, Kengo Tanabe, Yoshisato Shibata, Mafumi Owa, Seiji Hokimoto, Kkunihiro Nishimura, Yoshihiro Miyamoto, Takashi Muramatsu, Yousuke Hashimoto, Hiroshi Takahashi, Hisao Ogawa
Journal: Journal of the American College of Cardiology (2015)
The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients
Authors: Frank Giles, Sarina A. Piha-Paul, Alexander I. Spira, Fadi Braiteh, Julio Antonio Peguero, Daniel L. Spitz, James A. Knost, Lee Schwartzberg, Steven Stein, August J. Salvado, Claudia Lebedinsky, Barinder Kang, Eric Slosberg
Journal: Blood (2014)
TCT-170 Safety and efficacy of bivalirudin during percutaneous intervention in acute coronary syndrome in the real world. The CARTAGOMAX study
Authors: Jose D. Cascon, José Abellán-Huerta, Tamara Archondo-Arce, Miryam Martínez-Pascual-de-Riquelme, Irene-Azenaia García-Escribano-García, Santiago Sánchez-Argente-del-Castillo, F. Guillermo Clavel-Ruipérez, Pablo Ramos-Ruiz, María-Lucía Fernández-Gassó, Erika Muñoz-García, Juan A. Castillo-Moreno
Journal: Journal of the American College of Cardiology (2015)
Notice of Retraction and Replacement. Schopfer DW, et al. Cardiac Rehabilitation Use Among Veterans With Ischemic Heart Disease. JAMA Intern Med. 2014;174(10):1687-1689
Authors: David W. Schopfer, Steven Takemoto, Kelly Allsup, Christian D. Helfrich, P. Michael Ho, Daniel E. Forman, Mary A. Whooley
Journal: JAMA Internal Medicine (2016)
Health-related quality of life (QoL) in patients with seminoma stage I treated with either adjuvant radiotherapy (RT) or two cycles of carboplatinum chemotherapy (CT): Results of a randomized phase III trial of the German Interdisciplinary Working Party on Testicular Cancer
Authors: P. Schoffski, N. Höhn, R. Kowalski, J. Classen, C. Meisner, G. Fechner, K. Dieckmann, C. Winkler, M. Bamberg
Journal: Journal of Clinical Oncology (2007)

5050 Background: RT and CT are efficient adjuvant therapies in seminoma stage I and were compared in this trial. Clinical results will be reported elsewhere. Secondary endpoint was to assess QoL. Materials and Methods: Pts were randomized to receive RT (5x2 Gy/wk, 26–30 Gy total dose) or carboplatinum (300–460 mg/m 2 , 1 h iv d 1, 29). The QLQ C30 vs. 2.0 (15 QoL dimensions) and the Testicular Tumour Questionnaire (TTQ, 16 domains) were completed at randomization (0) and 1, 4, and 12 months (m) after trial entry. QoL was compared over time within the two arms (Wilcoxon) and between treatments (Mann-Whitney) by intent-to-treat. Results: 807 pts were randomized. Questionnaire compliance was 72% at 0, 75% at 1, 69% at 4 and 70% at 12m. Sign. variation (p&lt;0.05) in QoL over time in both treatment arms (no. of Qol domains with deterioration over time): QLQ C30: RT: m1 vs 0 9, m4 vs 0 2, m12 vs 0 0 , CT: m1 vs 0 6, m4 vs 0 3, m12 vs 0 1; TTQ: RT: m1 vs 0 4, m4 vs 0 2, m12 vs 0 3, CT: m1 vs 0 1, m4 vs 0 2, m12 vs 0 1. (¼ improvement over time): QLQ C30: RT: m1 vs 0 0, m4 vs 0 6, m12 vs 0 8, CT: m1 vs 0 2, m4 vs 0 6, m12 vs 0 10; TTQ: RT: m1 vs 0 1, m4 vs 0 2, m12 vs 0 3, CT: m1 vs 0 2, m4 vs 0 4, m12 vs 0 6. Sign. variation in QoL comparing treatment modalities: QLQ C30: Better QoL in RT: at m1 in 0, at m4 in 0 and at m12 in 0 domains, Better QoL in CT: at m1 in 11, at m4 in 2 and at m12 in 5 domains; TTQ: Better QoL in RT: at m1 in 4, at m4 in 1 and at m12 in 0 domains, Better QoL in CT: at m1 in 3, at m4 in 0 and at m12 in 2 domains. Discussion and Conclusions: Adjuvant RT has a more negative impact on self-reported QoL of seminoma pts than CT, as determined by two instruments over a period of one year. RT negatively affects more dimensions of QoL as compared to CT, especially during the early phase. Pts rapidly adapt to QoL impairment, with little change persisting at m12. Not all observed differences are clinically relevant. Potential bias and methodological limitations will be discussed. Given the presumed clinical equivalence of both modalities, pts should be aware of the more negative impact of RT on the well-being. Treatment recommendation should be based on objective outcome parameters, toxicity, logistics and QoL considerations. No significant financial relationships to disclose.
TCT-615 First Report of Three-Year Outcomes With the Repositionable and Fully Retrievable Lotus Aortic Valve Replacement System: Results From the REPRISE I Feasibility Study
Authors: Ian T. Meredith, Stephen G. Worthley, Robert J. Whitbourn, Joseph Montarello, Andrew E. Newcomb, Dominic J. Allocco, Keith D. Dawkins
Journal: Journal of the American College of Cardiology (2015)
TCT-541 Absorb Bioresorbable Vascular Scaffold: ultrastructural changes assessed by transmission electron microscopy in the porcine coronary model
Authors: Tobias Koppara, Russell M. Jones, Fumiyuki Otsuka, Laura E. Perkins, Erica Pacheco, Oscar D. Sanchez, Kazuyuki Yahagi, Hiroyoshi Mori, Frank D. Kolodgie, Renu Virmani, Michael Joner
Journal: Journal of the American College of Cardiology (2015)
TCT-501 A propensity-matched study comparing overlapping bioresorbable scaffolds versus new generation everolimus eluting stents
Authors: Vasileios F. Panoulas, Hiroyoshi Kawamoto, Katsumasa Sato, Tadashi Miyazaki, Toru Naganuma, Alaide Chieffo, Mauro Carlino, Matteo Montorfano, Azeem Latib, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)
Polymorphisms In Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor Type 1 In Women With Primary Recurrent Pregnancy Loss
Authors: Juliano Felix Bertinato, Vânia Maris Morelli, Guilherme Gomes Wataru, Antonio Gomes de Amorim Filho, Mario Henrique Burlachini de Carvalho, Marcelo Zugaib, Elvira Maria Guerra-Shinohara
Journal: Blood (2013)
Abstract POSTER-THER-1425: Novel small molecules overcoming platinum drug resistance in ovarian cancer cells
Authors: Wei Qian, Jingnan Wang, Robert Edwards, Peter Wipf, Bennett Van Houten
Journal: Clinical Cancer Research (2015)

Abstract After stage, platinum drug resistance is the single most important factor in determining prognosis in ovarian cancer. Overcoming platinum drug resistance by pharmacological manipulations represents a major challenge in the current clinical practice for the management of ovarian cancer. We discovered a novel drug combination approach using platinum agents with mdivi-1 (mitochondrial division inhibitor 1) that is able to synergistically induce rapid apoptosis in platinum-resistant ovarian cancer cells, including established cisplatin-resistant ovarian cancer cell lines as well as primary cancer cells derived from ovarian cancer patients. We also identified that the synergism between cisplatin and mdivi-1 is not dependent on Drp1 (a mitochondrial fission protein and the reported target of mdivi-1), as mdivi-1 enhances cisplatin toxicity in Drp1 knockout mouse embryonic fibroblast (MEF) cells. In order to improve the compound properties of mdivi-1, we performed a structure activity relationship (SAR) study of mdivi-1 and assembled and screened a small library of structurally related compounds. We were able to identify more potent novel small molecules that synergize with platinum agents. We found that short-term exposure of cells to the combination of cisplatin and those novel compounds is sufficient to reduce cell viability, while cisplatin alone treatment only slightly inhibited cell proliferation in cisplatin-resistant ovarian cancer cells. We further identified that mdivi-1 and its structurally related novel small molecules, when combined with cisplatin, induce a synergistic increase of replication stress and DNA damage, causing upregulation of a pro-apoptotic Bcl-2 family protein Noxa. These small molecules also repress mitochondrial respiration and the combination with cisplatin triggers substantial mitochondrial dysfunction including mitochondrial uncoupling. DNA replication stress and mitochondrial dysfunction converge on the induction of mitochondrial outer membrane permeabilization (MOMP) proceeding robust mitochondrial apoptotic signaling, bypassing a Bax/Bak-dependent mechanism. Since apoptosis induced by cisplatin alone relies on Bax/Bak-dependent MOMP, and inefficient activation of Bax/Bak-dependent MOMP is often associated with cisplatin resistance, the combination of cisplatin and mdivi-1 family compounds represents a novel strategy in overcoming platinum resistance. We thus present a novel platinum-based combination approach in the treatment of platinum resistant ovarian cancer. Citation Format: Wei Qian, Jingnan Wang, Robert Edwards, Peter Wipf, Bennett Van Houten. Novel small molecules overcoming platinum drug resistance in ovarian cancer cells [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-THER-1425.
Antithrombin-Independent Thrombin Inhibitors, but Not Factor Xa Inhibitors, Enhance Thrombin Generation in Human Plasma Via Inhibition of Thrombin-Thrombomodulin-Protein C System.
Authors: Yoshiyuki Morishima, Taketoshi Furugohri, Yoko Shiozaki, Nobutoshi Sugiyama, Toshiro Shibano
Journal: Blood (2006)
French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404)
Authors: Francoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros-Miralles, Regis Peffault Delatour, Jean-Hugues Dalle, Eleonore Petras, Valentine Brousse, Isabelle Thuret, Catherine Paillard, Benedicte Neven, Claire Galambrun, Maryse Etienne-Julian, Corinne Pondarre, Laurence Lutz, Corinne Guitton, Florence Missud, Camille Runel, Charlotte Jubert, Gisele Elana, Manuela Vasile, Cecile Arnaud, Annie Kamdem, Florence Kasbi, Francois Gouraud, Francoise Freard, Fabienne Toutain, Gerard Socie, Sylvie Chevret
Journal: Blood (2015)
Transient Receptor Potential Vanilloid 4–Mediated Disruption of the Alveolar Septal Barrier
Authors: Diego F. Alvarez, Judy A. King, David Weber, Emile Addison, Wolfgang Liedtke, Mary I. Townsley
Journal: Circulation Research (2006)

Disruption of the alveolar septal barrier leads to acute lung injury, patchy alveolar flooding, and hypoxemia. Although calcium entry into endothelial cells is critical for loss of barrier integrity, the cation channels involved in this process have not been identified. We hypothesized that activation of the vanilloid transient receptor potential channel TRPV4 disrupts the alveolar septal barrier. Expression of TRPV4 was confirmed via immunohistochemistry in the alveolar septal wall in human, rat, and mouse lung. In isolated rat lung, the TRPV4 activators 4alpha-phorbol-12,13-didecanoate and 5,6- or 14,15-epoxyeicosatrienoic acid, as well as thapsigargin, a known activator of calcium entry via store-operated channels, all increased lung endothelial permeability as assessed by measurement of the filtration coefficient, in a dose- and calcium-entry dependent manner. The TRPV antagonist ruthenium red blocked the permeability response to the TRPV4 agonists, but not to thapsigargin. Light and electron microscopy of rat and mouse lung revealed that TRPV4 agonists preferentially produced blebs or breaks in the endothelial and epithelial layers of the alveolar septal wall, whereas thapsigargin disrupted interendothelial junctions in extraalveolar vessels. The permeability response to 4alpha-phorbol-12,13-didecanoate was absent in TRPV4(-/-) mice, whereas the response to thapsigargin remained unchanged. Collectively, these findings implicate TRPV4 in disruption of the alveolar septal barrier and suggest its participation in the pathogenesis of acute lung injury.
TCT-166 Angiographic and Long-term Clinical Outcomes after Bare-metal, First-generation, and Second-generation Drug-eluting Stent Implantation for Left Main Coronary Artery Disease: from the Japanese Left Main Coronary Stenting Registry
Authors: Masanobu Ohya, Kazushige Kadota, Yasushi Fuku, Mamoru Toyofuku, Hirooki Higami, Kyohei Yamaji, Hiromi Muranishi, Yuhei Yamaji, Koji Nishida, Daisuke Furukawa, Tomohisa Tada, Euihong Ko, Kenji Ando, Hiroki Sakamoto, Takashi Tamura, Kazuya Kawai, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2015)
GW27-e1119 Resheathable self-expanding transcatheter aortic valve system: 1-year high volume centre experience
Authors: James Shue Min Yeh, Mao Liu, Shufang Wang, Tito Kabir, Alison Duncan, Anan Daqa, Francesca Calicchio, Cesare Quarto, Rashmi Yadav, Jian Chen, Eleanor Dunnett, Carlo Di Mario, Miles Dalby, Simon William Davies, Neil Moat
Journal: Journal of the American College of Cardiology (2016)
Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies
Authors: Stefanie Derer, Pia Glorius, Martin Schlaeth, Stefan Lohse, Umesh Muchhal, John Desjarlais, Andreas Humpe, Thomas Valerius, Matthias Peipp
Journal: Blood (2013)
Prevalence and Causes of Attrition Among Surgical Residents
Authors: Zeyad Khoushhal, Mohamad A. Hussain, Elisa Greco, Muhammad Mamdani, Subodh Verma, Ori Rotstein, Andrea C. Tricco, Mohammed Al-Omran
Journal: JAMA Surgery (2016)

Attrition of residents from general surgery training programs is relatively high; however, there are wide discrepancies in the prevalence and causes of attrition reported among surgical residents in previous studies.To summarize the estimate of attrition prevalence among general surgery residents.We searched the Medline, EMBASE, Cochrane, PsycINFO, and ERIC databases (January 1, 1946, to October 22, 2015) for studies reporting on the prevalence and causes of attrition in surgical residents, as well as the characteristics and destinations of residents who left general surgery training programs. Database searches were conducted on October 22, 2015.Eligibility criteria included all studies reporting on the primary (attrition prevalence) or secondary (causes of attrition and characteristics and destination of residents who leave residency programs) outcomes in peer-reviewed journals. Commentaries, reviews, and studies reporting on preliminary surgery programs were excluded. Of the 41 full-text articles collected from the title/abstract screening, 22 studies (53.7%) met the selection criteria.Two reviewers independently collected and summarized the data. We calculated pooled estimates using random effects meta-analyses where appropriate.Attrition prevalence of general surgery residents.Overall, we included 22 studies that reported on residents (n = 19 821) from general surgery programs. The pooled estimate for the overall attrition prevalence among general surgery residents was 18% (95% CI, 14%-21%), with significant between-study variation (I2 = 96.8%; P < .001). Attrition was significantly higher among female compared with male (25% vs 15%, respectively; P = .008) general surgery residents, and most residents left after their first postgraduate year (48%; 95% CI, 39%-57%). Departing residents often relocated to another general surgery program (20%; 95% CI, 15%-24%) or switched to anesthesia (13%; 95% CI, 11%-16%) and other specialties. The most common reported causes of attrition were uncontrollable lifestyle (range, 12%-87.5%) and transferring to another specialty (range, 19%-38.9%).General surgery programs have relatively high attrition, with female residents more likely to leave their training programs than male residents. Residents most often relocate or switch to another specialty after the first postgraduate year owing to lifestyle-related issues.
GW27-e0405 Study on the compatibility of Blood Activation and Qi Supplement prescription(BAQS) on angiogenesis regulated by the expression of miR-126 and Spred1 in rats after AMI
Authors: Wenkun Cheng, Meng Chen, Ruiling Zheng, Lixia Lou, Aiming Wu, Xuejiao Ren, Yifei Qi, Dongmei Zhang
Journal: Journal of the American College of Cardiology (2016)
No Impact of Dectin-1 Polymorphism Y238X On the Outcome of Hematopoietic Stem Cell Transplantation, but a Role for Candida in Acute Graft-Versus-Host Disease.
Authors: Walter J.F.M. van der Velden, Theo Plantinga, Ton Feuth, Peter Donnelly, Mihai Netea, Nicole N.A. Blijlevens
Journal: Blood (2009)
Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50–100 × 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts
Authors: Moshe Talpaz, Ronald Paquette, Lawrence Afrin, Solomon Hamburg, Katarzyna Jamieson, Howard Terebelo, Gregory Ortega, Roger M. Lyons, Ramon V. Tiu, Elliott F. Winton, Kavita Natrajan, Olatoyosi Odenike, Wei Peng, Victor A. Sandor, Peter O'Neill, Sue Erickson-Viitanen, Lance Leopold, Richard S Levy, Hagop M Kantarjian, Srdan Verstovsek
Journal: Blood (2012)
TCT-30 PREMIUM Trial: Double blind study of percutaneous closure of patent foramen ovale with the AMPLATZER® PFO Occluder as a treatment for migraine with or without aura
Authors: Jonathan Tobis, Andrew Charles, Stephen D. Silberstein, Sherman Sorensen, Brij Maini, Phillip A. Horwitz, John c Gurley
Journal: Journal of the American College of Cardiology (2015)
TCT-436 Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study
Authors: Holger Nef, Karl Eugen Hauptmann, Azeem Latib, Lynn Morrison, Sara Toyloy, Lynn Vandertie, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
TCT-280 Impact of Diabetes Mellitus on Graft Patency following Coronary Artery Bypass Graft Surgery: a Propensity Score Analysis
Authors: Mohamed Ayan, Alok Saurav, Amjad Kabach, Aiman Smer, Mohsin Salih, Ahmed Abuzaid, Muhammad S. Azzouz, Abhilash Akinapelli, Saurabh Aggarwal, Mohamed El Khashab, Venkata M. Alla, Claire Hunter, Aryan Mooss
Journal: Journal of the American College of Cardiology (2015)
Amplification of 6p Associated with Familial CLL
Authors: Jennifer R Brown, Bethany Tesar, Megan Hanna, Megan Ash, Stacey M Fernandes, Laura Macconaill, Ursula Hainz, Janina Longtine, Catherine J Wu, Lillian Werner, Yaoyu Wang, Mick Correll, Donna Neuberg, Arnold S. Freedman
Journal: Blood (2010)
GW27-e0509 Contrast-enhanced ultrasound imaging of intraplaque neovascularization and its correlation to plaque echogenicity in human carotid arteries atherosclerosis
Authors: Mattia Cattaneo, Daniel Staub, Alessandra P. Porretta, Jeanne Marie Gallino, Paolo Santini, Magdalena M. Pawelec, Costanzo Limoni, Rolf Wyttenbach, Augusto Gallino
Journal: Journal of the American College of Cardiology (2016)
Announcing the New JAMACardiology.com
Authors: Paul Gee, Colleen Kelly, Michael Berkwits, Robert O. Bonow
Journal: JAMA Cardiology (2016)

This week JAMA Cardiology and The JAMA Network launch a new online platform at jamacardiology.com.We have cocreated the sites with you-our users-combining data about how the sites are used with extensive input from clinician and author colleagues to redesign every page focusing on our mosttrafficked article pages.We have aimed to make the platform more usable, discoverable, and faster on any device.
High-grade bone sarcomas with synchronous metastases in patients older than 40. Results of the European Bone over 40: Sarcoma Study (EURO.B.O.S.S.)
Authors: M. Cesari, A. Comandone, A. Boglione, V. Ferraresi, R. Bertulli, S. Bielack, K. Sundby Hall, M. Rocca, D. Donati, E. Palmerini, A. Paioli, A. Longhi, M. Gambarotti, A. Righi, P. Picci, S. Ferrari
Journal: Annals of Oncology (2015)
Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),
Authors: Flora Peyvandi, Roberta Palla, Marzia Menegatti, Simona M Siboni, Susan Halimeh, Britta Faeser, Helen Pergantou, Heleni Platokouki, Paul Giangrande, Kathelijne Peerlink, Tiraje Celkan, Nihal Ozdemir, Christoph Bidlingmaier, Jorgen Ingerslev, Muriel Giansily-Blaizot, Jean-Francois Schved, Ruth Gilmore, Alain P. Gadisseur, Majda Benedik-Dolnicar, Lidija Kitanovski, Danijela Mikovic, Khaled M Musallam, Frits R. Rosendaal
Journal: Blood (2011)
The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial
Authors: Simon Rule, Paul Smith, Peter W Johnson, Simon Bolam, George A Follows, Jo Gambell, Peter Hillmen, Andrew Jack, Stephen A. N. Johnson, Amy Kirkwood, Anton Kruger, John F. Seymour, Milena Toncheva, Jan Walewski, David C Linch
Journal: Blood (2011)
Direct Intra-Bone Cord-Blood Transplantation Overcomes the Problem of Graft Failure Even When Low Numbers of HLA-Mismatched Cord- Blood Cells Are Transplanted, Thus Leading to the Possibility of Use of This Technique in a Large Number of Patients.
Authors: Francesco Frassoni, Franca Fagioli, Marina Podestà, Francesca Gualandi, Massimo Berger, Francesca Nesi, Annamaria Raiola, Adalberto Ibatici, Marco Gobbi, Myriam Labopin, Andrea Bacigalupo
Journal: Blood (2008)
A Phase I/II Trial of Gemtuzumab Ozogamicin in Combination with Cytarabine and Anthracyclines (Daunorubicin or Idarubicin) for CD33-Positive Refractory or Relapsed AML Patients Younger Than 65 Years. Results of Phase I Parts of the JALSG-AML206 Study.
Authors: Noriko Usui, Akihiro Takeshita, Chiaki Nakaseko, Nobuaki Dobashi, Hiroyuki Fujita, Hitoshi Kiyoi, Yukio Kobayashi, Shin Fujisawa, Fumiharu Yagasaki, Kazuhiro Nishii, Toru Kiguchi, Yasushi Miyazaki, Shigeki Ohtake, Shuichi Miyawaki, Ryuzo Ohno, Tomoki Naoe, Kazunori Ohnishi
Journal: Blood (2009)
The Adipokine-Cardiovascular-Lifestyle Network
Authors: Jeffrey I. Mechanick, Shan Zhao, W. Timothy Garvey
Journal: Journal of the American College of Cardiology (2016)

Adipokines are peptides, secreted by adipocytes and other cell types with targets in other tissues, participating in a complex network of humoral factors involved in obesity, insulin resistance, and cardiovascular (CV) disease. This review describes recent information about adipokine effects on the CV system. Rather than simply providing a listing of adipokines and their respective effects, network analysis is used to enhance understanding. Various relationships and emergent processes in the adipokine-CV system network are discussed, with the most significant interactors being responses to hypoxia, regulation of cell migration, effects on blood coagulation, and platelet activation. Clinical translation is provided through network representations of the "obesity paradox," "metabolically healthy obese," "metabolic syndrome," and beneficial role of lifestyle medicine. As more translatable information about the larger adipokine-CV-lifestyle network is acquired from laboratory and clinical research, the strategic and precise role of lifestyle intervention can be fashioned to improve CV outcomes.
GW27-e0291 Elevated serum levels of immunoglobulin E promote the development of calcific aortic valve disease
Authors: Zheng Yunyi, Qingchun Zeng, Xi Yang, Shengping He, Jinghai Hua, Zuheng Liu, Dongqi An, Dingji Zhu, Dingli Xu
Journal: Journal of the American College of Cardiology (2016)